Attached files
| file | filename |
|---|---|
| 8-K - PDL BIOPHARMA, INC. | v208856_8k.htm |
| EX-10.1 - PDL BIOPHARMA, INC. | v208856_ex10-1.htm |
|
Contacts:
|
|
|
Cris Larson
|
Jennifer
Williams
|
|
PDL BioPharma,
Inc.
|
Cook Williams Communications,
Inc.
|
|
775-832-8505
|
360-668-3701
|
|
Cris.Larson@pdl.com
|
jennifer@cwcomm.org
|
PDL
BioPharma Appoints Caroline Krumel as Vice President of Finance
and
Thanks Karen Wilson for her Contributions
INCLINE
VILLAGE, NV, January 25, 2011 – PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today
announced the appointment of Caroline Krumel, CPA to the position of vice
president of finance and chief accounting officer, effective January 31, 2011.
Ms. Krumel will replace Karen Wilson, who is leaving PDL to return to
California.
“Caroline
brings over 15 years of experience spearheading all financial functions in a
variety of private and public companies,” said John McLaughlin, president and
chief executive officer of PDL BioPharma. “Her financial acumen within agile
corporate environments coupled with her knowledge of financial and accounting
procedures make her an ideal fit for PDL as we manage our royalty assets and
evaluate additional royalty purchase opportunities.”
Before
joining the Company, Ms. Krumel most recently served as Vice President, Finance
from 2007 to 2010 at VaxGen Inc., a public company focused on the development of
vaccinations until a merger transaction with diaDexus, Inc. in 2010. From 2006
to 2007, Ms. Krumel worked for Frank, Rimerman + Co. LLP, one of the largest
locally-owned providers of accounting and consulting services in Northern
California, where she delivered accounting services for various companies. Prior
to 2006, Ms. Krumel worked at Santa Clara University in the Department of
Accounting (academic), where she was instrumental in increasing student
enrollment in the department’s advanced accounting certificate
program. Ms. Krumel is a certified public accountant and holds a
Master of Public Management from the University of Maryland at College Park and
a Bachelor of Arts in Political Science with honors from the University of North
Carolina at Chapel Hill.
“On
behalf of PDL,” John McLaughlin said, “I want to thank Karen for her numerous
contributions and wish her continued success in her future ventures.” Ms.
Wilson, who joined the Company in April 2009, was instrumental in helping the
Company accomplish many transition-related goals relating to both the spin-off
of Facet Biotech Corporation and the Company’s relocation to Nevada. Ms. Wilson
has made a number of significant contributions to the Company, including the
winding-up of certain pre-2009 activities and helping establish the
infrastructure necessary to facilitate the Company’s accounting and financial
reporting going forward.
About PDL BioPharma
PDL pioneered the humanization of
monoclonal antibodies and, by doing so, enabled the discovery of a new
generation of targeted treatments for cancer and immunologic diseases. PDL is
focused on maximizing the value of its antibody humanization patents and related
assets. The Company receives royalties on sales of a number of humanized
antibody products marketed by leading pharmaceutical and biotechnology companies
today based on patents which expire in late 2014. For more information, please
visit www.pdl.com.
NOTE: PDL BioPharma and the PDL
BioPharma logo are considered trademarks of PDL BioPharma,
Inc.
###